460 related articles for article (PubMed ID: 31451496)
1. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment.
Woodburn KW; Clemens LE; Jaynes J; Joubert LM; Botha A; Nazik H; Stevens DA
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451496
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of Candida species isolated from vaginal infections.
Scarsini M; Tomasinsig L; Arzese A; D'Este F; Oro D; Skerlavaj B
Peptides; 2015 Sep; 71():211-21. PubMed ID: 26238597
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activity of analogues of antimicrobial peptides isolated from bee venoms against vulvovaginal Candida spp.
Kočendová J; Vaňková E; Volejníková A; Nešuta O; Buděšínský M; Socha O; Hájek M; Hadravová R; Čeřovský V
FEMS Yeast Res; 2019 May; 19(3):. PubMed ID: 30753486
[TBL] [Abstract][Full Text] [Related]
4. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
Gao M; Wang H; Zhu L
Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337
[TBL] [Abstract][Full Text] [Related]
5. Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Ng SM; Yap YY; Cheong JW; Ng FM; Lau QY; Barkham T; Teo JW; Hill J; Chia CS
J Pept Sci; 2017 Mar; 23(3):215-221. PubMed ID: 28105725
[TBL] [Abstract][Full Text] [Related]
6. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Sherry L; Kean R; McKloud E; O'Donnell LE; Metcalfe R; Jones BL; Ramage G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696240
[TBL] [Abstract][Full Text] [Related]
7. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Adjapong G; Hale M; Garrill A
Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
[TBL] [Abstract][Full Text] [Related]
8. Differential Response of
Salama OE; Gerstein AC
Antimicrob Agents Chemother; 2022 May; 66(5):e0240621. PubMed ID: 35446135
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
Hacioglu M; Guzel CB; Savage PB; Tan ASB
Med Mycol; 2019 Apr; 57(3):291-299. PubMed ID: 29846682
[TBL] [Abstract][Full Text] [Related]
10. Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates.
Alvendal C; Mohanty S; Bohm-Starke N; Brauner A
PLoS One; 2020; 15(9):e0238428. PubMed ID: 32941438
[TBL] [Abstract][Full Text] [Related]
11. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of spider venom-derived peptide lycosin-I against Candida tropicalis.
Tan L; Bai L; Wang L; He L; Li G; Du W; Shen T; Xiang Z; Wu J; Liu Z; Hu M
Microbiol Res; 2018 Nov; 216():120-128. PubMed ID: 30269852
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant Candida albicans.
Ng SMS; Yap JM; Lau QY; Ng FM; Ong EHQ; Barkham T; Teo JWP; Alfatah M; Kong KW; Hoon S; Arumugam P; Hill J; Brian Chia CS
Eur J Med Chem; 2018 Apr; 150():479-490. PubMed ID: 29549835
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.
Boikov DA; Locke JB; James KD; Bartizal K; Sobel JD
J Antimicrob Chemother; 2017 May; 72(5):1355-1358. PubMed ID: 28158577
[TBL] [Abstract][Full Text] [Related]
15. Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern.
Khaksar Baniasadi A; Ayatollahi Mosavi SA; Sharifi I; Bamorovat M; Salari S; Ahmadi A; Amanizadeh A; Agha Kuchak Afshari S
J Obstet Gynaecol Res; 2022 Dec; 48(12):3292-3303. PubMed ID: 36184563
[TBL] [Abstract][Full Text] [Related]
16. Biofilms and vulvovaginal candidiasis.
Rodríguez-Cerdeira C; Gregorio MC; Molares-Vila A; López-Barcenas A; Fabbrocini G; Bardhi B; Sinani A; Sánchez-Blanco E; Arenas-Guzmán R; Hernandez-Castro R
Colloids Surf B Biointerfaces; 2019 Feb; 174():110-125. PubMed ID: 30447520
[TBL] [Abstract][Full Text] [Related]
17. Synthetic antimicrobial β-peptide in dual-treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm Candida albicans.
Mora-Navarro C; Caraballo-León J; Torres-Lugo M; Ortiz-Bermúdez P
J Pept Sci; 2015 Dec; 21(12):853-61. PubMed ID: 26470850
[TBL] [Abstract][Full Text] [Related]
18. Vulvovaginal candidiasis in a Flemish patient population.
De Vos MM; Cuenca-Estrella M; Boekhout T; Theelen B; Matthijs N; Bauters T; Nailis H; Dhont MA; Rodriguez-Tudela JL; Nelis HJ
Clin Microbiol Infect; 2005 Dec; 11(12):1005-11. PubMed ID: 16307555
[TBL] [Abstract][Full Text] [Related]
19. Phytolectin nanoconjugates in combination with standard antifungals curb multi-species biofilms and virulence of vulvovaginal candidiasis (VVC) causing Candida albicans and non-albicans Candida.
Senthilganesh J; Kuppusamy S; Durairajan R; Subramaniyan SB; Veerappan A; Paramasivam N
Med Mycol; 2022 Jan; 60(2):. PubMed ID: 34958385
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Sobel JD; Sobel R
Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
